(VIANEWS) – The Market ended the session with ULTIMOVACS (ULTI.OL) jumping 13.27% to kr7.17 on Friday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI jumped 0.67% to kr1,319.33, after five consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.
ULTIMOVACS’s last close was kr6.33, 96.46% below its 52-week high of kr178.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.5.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.94%.
Moving Average
ULTIMOVACS’s worth is way under its 50-day moving average of kr119.29 and way below its 200-day moving average of kr99.42.
Yearly Top and Bottom Value
ULTIMOVACS’s stock is valued at kr7.17 at 21:36 EST, way under its 52-week high of kr178.60 and way higher than its 52-week low of kr6.50.
Volume
Today’s last reported volume for ULTIMOVACS is 1542190 which is 63.59% above its average volume of 942686.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ULTIMOVACS’s stock is considered to be overbought (>=80).
More news about ULTIMOVACS (ULTI.OL).
